October 25, 2023- Infants less than six months old that have chronic disease or underlying conditions should be given priority to receive the new RSV vaccine, because it is in short supply, according to the Centers for Disease Control (CDC).
U.S. physicians and the CDC told physicians to prioritize giving the drug to babies at the highest risk for severe disease. RSV, respiratory syncytial virus, which causes cold-like symptoms, can be more dangerous for young children, according to the CDC. The new FDA approved one-time RSV shot is given to children (less than 8 months old) to help their immune system fight off the virus.
Demand has been higher than expected, according to Sanofi and AstraZeneca, the developers of the drug, and demand for the product has been high, especially for the 100 mg doses used for babies born before RSV season. Sanofi is collaborating with the CDC to ensure proper distribution of the available doses, according to a recent statement.